The 30-share Sensex gained 117 points to end above 29,000 at 29,006 while the 50-share Nifty gained 32 points to close at 8,761.
ICICI Bank was the top Sensex gainer after S&P Global Ratings affirmed its 'BBB-' long-term issue ratings on the senior unsecured bonds.
Profit-booking and selling pressure on below-normal monsoon forecast, marred sentiments, traders said.
.jpg)
Markets ended flat on Tuesday, amid a volatile trading session, as investors exercised caution ahead of the two-day FOMC meet starting today and Reserve Bank of India's monetary policy later this week.
The parties intend to start the production of Sputnik V in the beginning of 2021, it added. Currently, Phase III clinical trials are approved and are ongoing in Belarus, the United Arab Emirates, Venezuela and other countries, as well as Phase II-III in India, RDIF said.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The 30-share BSE Sensex closed down 162 points at 28,338 and the 50-share Nifty was down 67 points at 8,463.
Shree Cement beats ACC in market value, Lupin ahead of Dr Reddy's Labs
The government should take measures to promote innovation and R&D while simplifying regulations for the sector in the upcoming Union Budget, as per pharmaceutical industry bodies. Outlining the wish list for the sector in the upcoming Union Budget, Indian Pharmaceutical Alliance (IPA) secretary general Sudarshan Jain said the domestic pharma industry is currently around $50 billion in size and aspires to grow to around $130 billion by 2030 and $450 billion by 2047. "To achieve this vision, the Union Budget 2023-2024 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry forward," he told PTI.
Traders are closely watching the progress of the monsoon.
Riding on a stock market boom since 2009, India Inc's chief executives have been able to salvage a lot of lost pride in their second innings.
Consumer businesses come to the rescue of large conglomerates in the midst of a meltdown in commodities.
Market breadth was weak with 1239 losers and 1078 gainers on the BSE.
Firms generated free cash flows in 2013-14, for the first time since the 2008 Lehman crisis
Nifty snaps 10-day winning streak
Dilip Shanghvi founded Sun Pharma in 1983.
IT sector's trading multiples hit post-Lehman lows, providing good entry points.
Financial shares were among the top gainers with HDFC leading the gains.
The 30-share Sensex provisionally ended up 46 points to end at 28,122 and the 50-share Nifty gained 20 points to close at 8,514.
Pharma shares were the top gainers led by Lupin after the company received EIR from USFDA for its Goa facility
Financial shares were among the top Sensex gainers along with auto and pharma shares.
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
The Sensex ended at at 27,676, lower by 210 points and the Nifty broke the psychological level of 8,400 to end at 83877 down 70 points.
The 30-share Sensex is up 253 points at 29,263 and the 50-share Nifty has gained 68 points at 8,829.
Infosys, TCS, HUL and Reliance Industries were the top gainers of the day.
The Sensex ended below 28,000 for the second straight day at 27,869.
Among key stocks, Tata Motors, Hero MotoCorp, L&T, Wipro, ICICI Bank, Dr Reddy's Labs and ICICI Bank, all up between 1%-3%
S&P upgraded India's credit outlook to 'stable' from 'negative' earlier.
Of these, three stocks belong to the automobile pack and two are from the pharma.
.jpg)
Banks, real estate and metal scrips among the top losers.
After a volatile session, Sensex closed the day 563 points lower
Markets ended lower for the third straight day on Tuesday weighed down by profit taking in rate sensitives with bank shares leading the decline after hopes of rate cut by the central bank faded.
The 30-share Sensex ended up 1 point at 27,459 and the 50-share Nifty ended down 1 point at 8,341.
The 30-share Sensex gained 271 points to end at 28,805 and the 50-share Nifty ended up 84 points at 8,712.
The Sensex ended higher by 245 points at 27,372 mark and the Nifty gained 66 points at 8,225.
The Sensex ended 229 points down at 27,602 and the Nifty ended down 63 points at 8,293.
Face NPPA fine for overcharging on anti-asthma drug
The ministry further stated that it was advisable to receive a complete schedule of the anti-coronavirus vaccine irrespective of past history of infection with COVID-19 as this will help in developing a strong immune response against the disease.
Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India seeking emergency use authorisation for their COVID-19 vaccines.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances